Tesamorelin vs Semax
A comprehensive, data-driven comparison of Tesamorelin (Egrifta) and Semax. Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Tesamorelin Egrifta, TH9507 | Semax |
|---|---|---|
| FDA Status | FDA Approved | Not submitted |
| Category | Growth Hormone | Cognitive Enhancement |
| Primary Use | HIV-associated lipodystrophy | Cognitive enhancement and neuroprotection |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $200 - $1,500/mo | $45 - $90/mo |
| Administration | Subcutaneous injection | Nasal spray |
| Typical Dose | 2mg daily | 2-3 drops per nostril 2-3x daily |
| Frequency | Daily | Daily |
| Mechanism | Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone production | Synthetic ACTH analog that enhances BDNF production, improves cerebral circulation, and protects neurons |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Moderate |
| Clinical Trial Phase | Approved | N/A |
Key Differences
- 1Tesamorelin is FDA-approved, while Semax is currently not submitted.
- 2Semax is generally more affordable ($45 - $90/mo) compared to Tesamorelin ($200 - $1,500/mo).
- 3Tesamorelin is administered via subcutaneous injection, while Semax uses nasal spray.
- 4Tesamorelin has high-quality evidence, while Semax has moderate-quality evidence.
- 5They belong to different categories: Tesamorelin (Growth Hormone) vs Semax (Cognitive Enhancement).
Which Is Better For...
Tesamorelin
Those seeking an FDA-approved treatment with established safety data
Semax
More budget-friendly option with lower monthly costs
Semax
Fewer commonly reported side effects
Tesamorelin
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Tesamorelin | $200 - $1,500/mo | FDA Approved | Theratechnologies |
| Semax | $45 - $90/mo | Not submitted | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Tesamorelin works via Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone. Semax works via Synthetic ACTH analog that enhances BDNF production, improves cerebral circulation, and protects. They differ in FDA approval status, efficacy data, and cost.
Tesamorelin typically costs $200 - $1,500/mo, while Semax costs $45 - $90/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Tesamorelin is FDA-approved. Semax is not FDA-approved (Not submitted). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Tesamorelin include Injection site reactions, Arthralgia, Peripheral edema. Common side effects of Semax include Nasal irritation, Mild stimulation, Headache. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Tesamorelin is an FDA-approved synthetic growth hormone releasing hormone analog specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. A new weekly reco...
View Full Tesamorelin GuideSemax is a synthetic peptide analog of adrenocorticotropic hormone (ACTH) developed in Russia. It has been shown to increase brain-derived neurotrophic factor (BDNF), improve cerebral blood flow, and ...
View Full Semax GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Tesamorelin and Semax should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.